{"doi":"10.3390/diseases13020051","title":"Clinical Impact of Olaparib for Platinum-Sensitive Recurrent Ovarian Cancer","abstract":"<jats:p>Background/Objectives: Olaparib, a poly ADP ribose polymerase inhibitor, has been effective in prolonging progression-free survival in platinum-sensitive recurrent ovarian cancer. The clinicopathological factors that predict a favorable prognosis remain unclear. Therefore, we retrospectively analyzed the prognostic effect of clinicopathological factors in the patients treated with olaparib for platinum-sensitive recurrent ovarian cancer. Methods: A total of 16 patients were treated with olaparib from 2018 to 2023. We categorized these patients into the responder (five cases who had not relapsed within 2 years) and non-responder groups (11 cases who had relapsed within 2 years). Clinical factors, including age, number of platinum drug courses, platinum-free interval, and CA125 value before olaparib treatment, were compared between the responder and non-responder groups. Results: The age of the responder group was significantly younger than that of the non-responder group (52 vs. 69 years old, p = 0.02). The CA125 value of the responder group was significantly lower than that of the non-responder group (14.2 vs. 82.7 U/mL, p = 0.02). Conclusions: The good predictive factors that enabled continued olaparib administration without recurrence were younger age and a lower CA125 value before olaparib treatment. The younger group (&lt;65 years old) and the low CA125 value group (&lt;20 U/mL) in PSR may be treated with olaparib for a long period, suppressing disease progression. Providing this information to patients with PSR may help in decision-making regarding performing maintenance therapy with olaparib.</jats:p>","journal":"Diseases","year":2025,"id":635361,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1648378,"name":"Megumi Manrai","orcid":null,"position":1,"is_corresponding":false},{"id":1648379,"name":"Akiko Takashima","orcid":null,"position":2,"is_corresponding":false},{"id":1648380,"name":"Hiroki Egashira","orcid":null,"position":3,"is_corresponding":false},{"id":1648381,"name":"Mizuki Nonaka","orcid":null,"position":4,"is_corresponding":false},{"id":1648382,"name":"Hideaki Shimada","orcid":null,"position":5,"is_corresponding":false},{"id":1648377,"name":"Hiroaki Ishida","orcid":"0000-0002-0629-3284","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Clinical Impact of Olaparib for Platinum-Sensitive Recurrent Ovarian Cancer","abstract":"<jats:p>Background/Objectives: Olaparib, a poly ADP ribose polymerase inhibitor, has been effective in prolonging progression-free survival in platinum-sensitive recurrent ovarian cancer. The clinicopathological factors that predict a favorable prognosis remain unclear. Therefore, we retrospectively analyzed the prognostic effect of clinicopathological factors in the patients treated with olaparib for platinum-sensitive recurrent ovarian cancer. Methods: A total of 16 patients were treated with olaparib from 2018 to 2023. We categorized these patients into the responder (five cases who had not relapsed within 2 years) and non-responder groups (11 cases who had relapsed within 2 years). Clinical factors, including age, number of platinum drug courses, platinum-free interval, and CA125 value before olaparib treatment, were compared between the responder and non-responder groups. Results: The age of the responder group was significantly younger than that of the non-responder group (52 vs. 69 years old, p = 0.02). The CA125 value of the responder group was significantly lower than that of the non-responder group (14.2 vs. 82.7 U/mL, p = 0.02). Conclusions: The good predictive factors that enabled continued olaparib administration without recurrence were younger age and a lower CA125 value before olaparib treatment. The younger group (&lt;65 years old) and the low CA125 value group (&lt;20 U/mL) in PSR may be treated with olaparib for a long period, suppressing disease progression. Providing this information to patients with PSR may help in decision-making regarding performing maintenance therapy with olaparib.</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39997058","pmcid":"PMC11854284","openalex_id":"https://openalex.org/W4407354335","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.02671836,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2079-9721/13/2/51/pdf","host_type":"journal"},{"url":"https://www.mdpi.com/2079-9721/13/2/51/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/diseases13020051","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39997058","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11854284","host_type":"repository"},{"url":"https://doaj.org/article/97fe23be5a9d44f3bc70c9c18fbec371","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11854284/pdf/diseases-13-00051.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11854284","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11854284?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["PARP inhibition in cancer therapy","Ovarian cancer diagnosis and treatment"],"mesh_terms":[],"keywords":["Olaparib","Medicine","Oncology","Ovarian cancer","Internal medicine","Gynecology","Cancer","Poly ADP ribose polymerase","Polymerase","CA125","Platinum-sensitive Recurrent Ovarian Cancer"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T14:58:27.923660Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}